LT3830092T - Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai - Google Patents
Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimaiInfo
- Publication number
- LT3830092T LT3830092T LTEPPCT/US2019/044814T LTUS2019044814T LT3830092T LT 3830092 T LT3830092 T LT 3830092T LT US2019044814 T LTUS2019044814 T LT US2019044814T LT 3830092 T LT3830092 T LT 3830092T
- Authority
- LT
- Lithuania
- Prior art keywords
- heteroaromatic
- nmda receptor
- receptor modulators
- nmda
- modulators
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862714100P | 2018-08-03 | 2018-08-03 | |
PCT/US2019/044814 WO2020086136A2 (en) | 2018-08-03 | 2019-08-02 | Heteroaromatic nmda receptor modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3830092T true LT3830092T (lt) | 2023-09-11 |
Family
ID=69228330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2019/044814T LT3830092T (lt) | 2018-08-03 | 2019-08-02 | Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai |
Country Status (37)
Country | Link |
---|---|
US (4) | US10584131B2 (lt) |
EP (2) | EP3830092B1 (lt) |
JP (1) | JP7319369B2 (lt) |
KR (1) | KR20210039432A (lt) |
CN (1) | CN112513047B (lt) |
AR (1) | AR115905A1 (lt) |
AU (1) | AU2019368147B2 (lt) |
BR (1) | BR112021001967A2 (lt) |
CA (1) | CA3108519A1 (lt) |
CL (1) | CL2021000294A1 (lt) |
CO (1) | CO2021002898A2 (lt) |
CR (1) | CR20210125A (lt) |
CU (1) | CU24647B1 (lt) |
CY (1) | CY1126144T1 (lt) |
DK (1) | DK3830092T3 (lt) |
DO (1) | DOP2021000025A (lt) |
EA (1) | EA202190431A1 (lt) |
EC (1) | ECSP21014902A (lt) |
ES (1) | ES2951872T3 (lt) |
FI (1) | FI3830092T3 (lt) |
HR (1) | HRP20230774T1 (lt) |
HU (1) | HUE062566T2 (lt) |
IL (1) | IL280474B2 (lt) |
JO (1) | JOP20210020A1 (lt) |
LT (1) | LT3830092T (lt) |
MA (1) | MA53351B1 (lt) |
MX (1) | MX2021001367A (lt) |
PE (1) | PE20210948A1 (lt) |
PH (1) | PH12021550242A1 (lt) |
PL (1) | PL3830092T3 (lt) |
PT (1) | PT3830092T (lt) |
RS (1) | RS64359B1 (lt) |
SG (1) | SG11202101125VA (lt) |
SI (1) | SI3830092T1 (lt) |
TW (1) | TWI833783B (lt) |
WO (1) | WO2020086136A2 (lt) |
ZA (1) | ZA202101273B (lt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3386591T (pt) * | 2015-12-09 | 2020-10-01 | Cadent Therapeutics Inc | Moduladores de recetores nmda heteroaromáticos e suas utilizações |
EP4006038A1 (en) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor modulators and uses thereof |
AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
EA202190431A1 (ru) | 2018-08-03 | 2021-06-11 | Кэйдент Терапьютикс, Инк. | Гетероароматические модуляторы nmda рецептора и их применение |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1067079A (en) | 1976-07-22 | 1979-11-27 | Yamanouchi Pharmaceutical Co. | Nitrogen-containing heterobicyclic compounds |
FR2549834B1 (fr) | 1983-07-25 | 1985-10-18 | Sanofi Sa | Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques |
US4921854A (en) | 1986-12-30 | 1990-05-01 | Egis Gyogyszergyar | Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds |
US5298502A (en) | 1988-12-12 | 1994-03-29 | Fmc Corporation | Method and composition for photodynamic treatment and detection of tumors |
WO1994027975A1 (de) | 1993-05-21 | 1994-12-08 | Pentapharm Ag | 3-(mercaptoalkyl)- bzw. 3-(alkylthioalkyl)-pyrimidin-2,4 (1h, 3h)-dione |
CA2257950A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
WO2002000629A1 (en) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
WO2003024955A2 (en) | 2001-09-18 | 2003-03-27 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
AR038118A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
EP1768960A1 (en) | 2004-07-13 | 2007-04-04 | F.Hoffmann-La Roche Ag | Sulfonamide derivatives |
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
CA2663161C (en) | 2006-09-11 | 2014-10-28 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
JP5271909B2 (ja) | 2006-09-11 | 2013-08-21 | エム・エス・ディー・オス・ベー・フェー | 2−(1−オキソ−1h−イソキノリン−2−イル)アセトアミド誘導体 |
AU2007333925B2 (en) | 2006-12-15 | 2013-10-31 | Nantbio, Inc. | Triazine derivatives and their therapeutical applications |
EP1939187A1 (en) | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
US8183276B2 (en) | 2007-02-08 | 2012-05-22 | Christian Fischer | Therapeutic agents |
US9034907B2 (en) | 2007-04-18 | 2015-05-19 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2008138126A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
JP5313246B2 (ja) | 2007-08-21 | 2013-10-09 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−iv阻害剤としてのヘテロシクリル化合物 |
TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
CN102083438B (zh) | 2008-05-01 | 2016-11-09 | 西特里斯药业公司 | 作为沉默信息调节因子的调节剂的喹啉和相关类似物 |
BRPI0913117A2 (pt) | 2008-05-29 | 2016-01-05 | Sirtris Pharmaceuticals Inc | imidazopiridina e análogos relacionados como moduladores de sirtuína |
EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
AU2009266889B2 (en) | 2008-07-03 | 2013-05-02 | Glaxosmithkline Llc | Benzimidazoles and related analogs as sirtuin modulators |
CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
WO2010037127A1 (en) | 2008-09-29 | 2010-04-01 | Sirtris Pharmaceuticals, Inc. | Chromenone analogs as sirtuin modulators |
WO2010079443A1 (en) | 2009-01-12 | 2010-07-15 | Pfizer Limited | Sulfonamide derivatives |
EP2411370B1 (en) | 2009-03-27 | 2015-04-22 | AbbVie Inc. | Compounds as cannabinoid receptor ligands |
EP2264035A1 (en) | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | Glycine B antagonists |
TW201116532A (en) | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
BR112012008518A2 (pt) | 2009-10-13 | 2016-04-05 | Msd Oss Bv | derivado heterocíclico, e, composição farmacêutica |
EP2552905B1 (en) | 2010-03-26 | 2016-10-05 | Boehringer Ingelheim International GmbH | B-Raf kinase inhibitors |
WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
US9066948B2 (en) | 2010-07-16 | 2015-06-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines |
WO2012052540A1 (en) | 2010-10-21 | 2012-04-26 | Universitaet Des Saarlandes | Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
US20120165330A1 (en) | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
MX361350B (es) | 2011-05-10 | 2018-12-04 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal de sodio. |
WO2013048928A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
EP2760840B1 (en) | 2011-09-30 | 2015-08-12 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
WO2013049104A1 (en) | 2011-09-30 | 2013-04-04 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
CN102336768A (zh) | 2011-10-24 | 2012-02-01 | 中国科学院上海有机化学研究所 | N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途 |
UA123760C2 (uk) | 2011-11-11 | 2021-06-02 | Гіліад Аполло, Ллс | Сполука (варіанти) та композиція, що містить сполуку |
WO2013119916A2 (en) | 2012-02-10 | 2013-08-15 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
WO2014066743A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
CN109369671B (zh) | 2013-06-28 | 2021-07-27 | 百济神州有限公司 | 作为Raf激酶和/或Raf激酶二聚体抑制剂的稠合三环脲类化合物 |
WO2015007453A1 (en) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
UY35751A (es) | 2013-09-26 | 2015-04-30 | Mnemosyne Pharmaceuticals Inc | Moduladores negativos de n-arilmetilo sulfonamida de nr2a |
ES2690355T3 (es) | 2013-10-11 | 2018-11-20 | F. Hoffmann-La Roche Ag | Tiazolopirimidinonas como moduladores de la actividad del receptor de NMDA |
WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する1-置換イミダゾピリミジノン誘導体 |
CN103664877A (zh) | 2013-12-25 | 2014-03-26 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
US9617226B2 (en) | 2014-09-05 | 2017-04-11 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
CR20170462A (es) | 2015-04-15 | 2018-02-01 | Hoffmann La Roche | Piridopirimidinonas y utilización de las mismas como moduladores de receptores nmda |
MX2018004553A (es) | 2015-10-16 | 2019-04-15 | Univ Northwestern | Combinación farmacéutica de un antipsicótico atípico y un modulador de nmda para el tratamiento de esquizofrenia, trastorno bipolar, deterioro cognitivo y trastorno depresivo mayor. |
EP4006038A1 (en) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor modulators and uses thereof |
PT3386591T (pt) | 2015-12-09 | 2020-10-01 | Cadent Therapeutics Inc | Moduladores de recetores nmda heteroaromáticos e suas utilizações |
WO2017188694A1 (ko) | 2016-04-25 | 2017-11-02 | 이뮤노메트테라퓨틱스 인코포레이티드 | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 |
WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
GEP20227429B (en) | 2017-09-27 | 2022-10-25 | Incyte Corp | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
EA202190431A1 (ru) | 2018-08-03 | 2021-06-11 | Кэйдент Терапьютикс, Инк. | Гетероароматические модуляторы nmda рецептора и их применение |
-
2019
- 2019-08-02 EA EA202190431A patent/EA202190431A1/ru unknown
- 2019-08-02 BR BR112021001967-7A patent/BR112021001967A2/pt unknown
- 2019-08-02 DK DK19876025.8T patent/DK3830092T3/da active
- 2019-08-02 PT PT198760258T patent/PT3830092T/pt unknown
- 2019-08-02 MA MA53351A patent/MA53351B1/fr unknown
- 2019-08-02 SG SG11202101125VA patent/SG11202101125VA/en unknown
- 2019-08-02 CN CN201980051645.9A patent/CN112513047B/zh active Active
- 2019-08-02 IL IL280474A patent/IL280474B2/en unknown
- 2019-08-02 AR ARP190102209A patent/AR115905A1/es unknown
- 2019-08-02 ES ES19876025T patent/ES2951872T3/es active Active
- 2019-08-02 MX MX2021001367A patent/MX2021001367A/es unknown
- 2019-08-02 LT LTEPPCT/US2019/044814T patent/LT3830092T/lt unknown
- 2019-08-02 WO PCT/US2019/044814 patent/WO2020086136A2/en active Application Filing
- 2019-08-02 JP JP2021529249A patent/JP7319369B2/ja active Active
- 2019-08-02 HR HRP20230774TT patent/HRP20230774T1/hr unknown
- 2019-08-02 EP EP19876025.8A patent/EP3830092B1/en active Active
- 2019-08-02 CU CU2021000013A patent/CU24647B1/es unknown
- 2019-08-02 RS RS20230563A patent/RS64359B1/sr unknown
- 2019-08-02 US US16/530,274 patent/US10584131B2/en active Active
- 2019-08-02 HU HUE19876025A patent/HUE062566T2/hu unknown
- 2019-08-02 PE PE2021000151A patent/PE20210948A1/es unknown
- 2019-08-02 KR KR1020217006300A patent/KR20210039432A/ko active Search and Examination
- 2019-08-02 JO JOP/2021/0020A patent/JOP20210020A1/ar unknown
- 2019-08-02 SI SI201930580T patent/SI3830092T1/sl unknown
- 2019-08-02 AU AU2019368147A patent/AU2019368147B2/en active Active
- 2019-08-02 EP EP23165151.4A patent/EP4223760A1/en active Pending
- 2019-08-02 CA CA3108519A patent/CA3108519A1/en active Pending
- 2019-08-02 PL PL19876025.8T patent/PL3830092T3/pl unknown
- 2019-08-02 FI FIEP19876025.8T patent/FI3830092T3/fi active
- 2019-08-02 TW TW108127473A patent/TWI833783B/zh active
- 2019-08-02 CR CR20210125A patent/CR20210125A/es unknown
- 2019-11-08 US US16/678,806 patent/US10752633B2/en active Active
-
2021
- 2021-02-01 PH PH12021550242A patent/PH12021550242A1/en unknown
- 2021-02-02 DO DO2021000025A patent/DOP2021000025A/es unknown
- 2021-02-03 CL CL2021000294A patent/CL2021000294A1/es unknown
- 2021-02-12 US US17/174,826 patent/US11542264B2/en active Active
- 2021-02-25 ZA ZA2021/01273A patent/ZA202101273B/en unknown
- 2021-03-03 CO CONC2021/0002898A patent/CO2021002898A2/es unknown
- 2021-03-03 EC ECSENADI202114902A patent/ECSP21014902A/es unknown
-
2023
- 2023-07-13 US US18/221,694 patent/US20240199617A1/en active Pending
- 2023-08-02 CY CY20231100387T patent/CY1126144T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201807731B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
IL276332A (en) | Spiro-lactam NMDA receptor modulators and their use | |
IL276330A (en) | Spiro-lactam NMDA receptor modulators and their use | |
IL264514A (en) | Spiro-lactam modulates and uses of the nmda receptor | |
IL286107A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
IL264488A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
EP3490994B8 (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
IL264397A (en) | Receptor regulators of chemokines and their uses | |
DK3830092T3 (en) | Heteroaromatic nmda receptor modulators and uses thereof | |
IL288858A (en) | Transmuted heteroaromatic pyrazolopyridines and their use as glun2b receptor modulators | |
IL276295A (en) | Modulators of chemokine receptors and their uses | |
EP3558318A4 (en) | NMDA RECEPTOR MODULATORS AND USES THEREOF | |
RS60834B1 (sr) | Modulatori heteroaromatskog nmda receptora i njihove upotrebe | |
HK1245259A1 (zh) | 作為nmda受體調節劑的吡啶並嘧啶酮類及它們的用途 | |
ZA201905511B (en) | Rorgamma modulators and uses thereof | |
ZA201905513B (en) | Rorgamma modulators and uses thereof | |
IL289575A (en) | nmda receptor modulators |